Assessment of localisation of vasodilatory response in CTEPH by SPECT imaging
Recruiting
- Conditions
- chronic thromboembolic pulmonary hypertensionincreased blood pressure in pulmonary vesels due to chronic pulmonary embolism1001928010014523
- Registration Number
- NL-OMON33993
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
-mean pulmonary artery pressure > 25 mmHg during right heart catherisation/ pulmonary angiography
-specific signs of chronic thromboembolism during pulmonary angiography
-Ntric monooxide testing during pulmonary angiography cq right heart pressure measuring
Exclusion Criteria
-Presence of systemic inflammation.
- Patients with pulmonary hypertension associated with collagen vascular disease, congenital heart disease, pulmonary venous hypertension, left heart failure, hypoxemic lung disease (COPD).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Macro aggregated albumin (MAA) injected in the peripheral vein distributes via<br /><br>the right heart (right ventricle) and pulmonary artery over both lungs; its<br /><br>distribution reflects the distribution of capillary perfusion at the time of<br /><br>injection.<br /><br><br /><br>The primary endpoint is the regional (lobar) change of biodistribution of MAA<br /><br>over both lungs under the influence of NO assessed with SPECT.<br /><br>Changes in perfusion counts between obstructed and non-obstructed regions of<br /><br>the lungs will be assessed to determine the vasodilatory response to NO with<br /><br>newly developed software (based upon published algorithms). According to our<br /><br>hypothesis the perfusion in the nonobstructed parts will increase after<br /><br>inhalation of NO.<br /><br><br /><br>In short, to determine the effect of NO on the regional pulmonary perfusion,<br /><br>using quantitative analysis of the SPECT data.</p><br>
- Secondary Outcome Measures
Name Time Method <p>To define the reproducibility of 99mTc- MAA biodistribution as assessed with<br /><br>SPECT another SPECT perfusion at baseline will be performed.</p><br>